Machine Learning Study Group
- Welcome to the 57th meeting, March 24, 2023.
- Status updates/news/inputs/comments
- Student status updates: PT showed a preliminary result which we discussed. VW is continuing to write his dissertation.
- Any other updates/news/inputs or comments?
- At the end of this blog entry is what happened when I asked ChatGPT to write a scientific paper.
- Next time: VK is away today but when he returns will continue stepping us through the article, "ChatGPT Strategy" by C. Goodall. We will start with the section "10 WAYS TEACHERS CAN USE CHAT GPT TO REDUCE WORKLOAD."
- We started reading GPT-4 is here: https://openai.com/research/gpt-4 and got up to the section heading "Capabilities."
- Here are some other things we could choose to read from in the future from as time allows.
- ChatGPT related readings, video viewings, etc.
- ChatGPT: What Is It & How Can You Use It? (searchenginejournal.com). We already read and discussed up to "The moderators at the coding Q&A website Stack Overflow ..." on 1/6/23.
- ChatGPT Is a Game-Changer. Here’s How to Use it in Your Writing. We already discussed more or less up to "2. Headline generation" on 12/30/22.
- ChatGPT Caused 'Code Red' at Google, Report Says - CNET. We already discussed up to "ChatGPT is an AI chatbot" on 12/30/22.
- 20 Entertaining Uses of ChatGPT You Never Knew Were Possible | by Mark Schaefer | Dec, 2022 | Medium
- Large Language Models: A New Moore's Law? (huggingface.co)
- The Brilliance and Weirdness of ChatGPT - The New York Times
- AI experts are increasingly afraid of what they’re creating
- Short video: ChatGPT in medicine
- At some point we can discuss and vote on other sources. See
the list on the page of sources. Also Youtube is full of videos about neural nets, transformers, etc.
- Readings/videos/demos we have finished.
- 2/17/23; "Deep Learning for AI" by Bengio, LeCun and Hinton, the Turing
Award Lecture paper for 2018, published in CACM, 2021, https://dl.acm.org/doi/pdf/10.1145/3448250.
- ChatGPT Is a Tipping Point for AI (Harvard Business Review). Finished 1/27/23.
- 12/16/22: We demoed ChatGPT.
- 11/4/22: We viewed and discussed a transformers video: https://www.youtube.com/watch?v=TQQlZhbC5ps first. This seemed to be one of the better videos of the many out there.
- Transformers From Scratch," https://e2eml.school/transformers.html. Finished on 10/28/22.
- The Narrated Transformer Language Model, Jay Alammar, https://www.youtube.com/watch?v=-QH8fRhqFHM, finished 7/22/22.
- https://www.youtube.com/watch?v=F1X4fHzF4mQ. Finished 8/26/22.
- We also finished other things from before this list of finished sources was created to keep a record of them.
- I asked ChatGPT to write a scientific paper. I used a series of leading questions like write an abstract, write the introduction, write the methods, write the results, write the conclusions, & write the list of references. I then asked it to suggest a list of journals and lesser known conferences where the new paper might be submitted.
ChatGPT:
Abstract:
We present a new study that investigates the effects of a novel drug, called "NeuroBoost," on cognitive function and brain activity in healthy adults. Using a randomized, double-blind, placebo-controlled design, we administered the drug or placebo to 50 participants and measured their cognitive performance using standardized tests and neuroimaging techniques.
Our results show that participants who received NeuroBoost had significantly improved cognitive performance compared to those who received placebo. Specifically, they showed better working memory, attention, and processing speed. Moreover, neuroimaging data revealed that NeuroBoost enhanced activity in brain regions associated with cognitive control and attentional processes.
These findings suggest that NeuroBoost has potential as a cognitive enhancer and could be used to improve cognitive function in healthy individuals. Further research is needed to investigate the long-term effects of this drug and its potential side effects.
ChatGPT:
Introduction:
Cognitive performance is crucial for various aspects of daily life, including work, education, and social interactions. Despite the advancements in modern medicine, there is still a need for safe and effective cognitive enhancers that can improve cognitive function in healthy individuals. This is particularly relevant in today's society, where individuals face increasing demands to perform cognitively challenging tasks.
In recent years, several drugs have been developed with the potential to enhance cognitive function. These drugs, collectively known as nootropics, have been widely used by individuals seeking to improve their cognitive performance. However, the efficacy and safety of these drugs remain controversial, and there is a need for further research to evaluate their effects.
In this study, we investigate the effects of a novel drug, called "NeuroBoost," on cognitive function and brain activity in healthy adults. NeuroBoost is a newly developed drug that is designed to enhance cognitive performance by targeting specific brain pathways involved in cognitive control and attentional processes.
To evaluate the efficacy of NeuroBoost, we employed a randomized, double-blind, placebo-controlled design, which is considered the gold standard in clinical research. We administered the drug or placebo to 50 participants and measured their cognitive performance using standardized tests and neuroimaging techniques.
The aim of this study is to provide empirical evidence on the effectiveness and safety of NeuroBoost as a cognitive enhancer. Our findings could have significant implications for the development of safe and effective cognitive enhancers and could pave the way for new approaches to improving cognitive function in healthy individuals.
ChatGPT:
Methods:
Participants: Fifty healthy adults aged 18-40 were recruited for the study through advertisements in local newspapers and online platforms. Participants were screened for any history of neurological or psychiatric disorders, drug abuse, or any medical conditions that could interfere with cognitive function. Participants were informed of the study procedures, risks, and benefits, and signed an informed consent form before participation.
Study design: This was a randomized, double-blind, placebo-controlled study. Participants were randomly assigned to either the NeuroBoost group or the placebo group. The study involved two sessions, one baseline session, and one follow-up session.
Procedure: During the baseline session, participants were given a battery of cognitive tests to assess their baseline cognitive performance. These tests included the Digit Span Test, the Trail Making Test, and the Stroop Test. After the baseline assessment, participants were administered a single dose of either NeuroBoost or placebo, which was prepared by an independent pharmacist.
The dose of NeuroBoost was determined based on the previous studies, which showed a safe and effective range of doses. The dose of placebo was matched in appearance, taste, and smell to NeuroBoost to ensure blinding.
After 60 minutes of taking the drug or placebo, participants underwent another round of cognitive tests to assess the acute effects of the drug. The cognitive tests used in the baseline session were repeated in the post-dose assessment.
Neuroimaging: In addition to cognitive testing, neuroimaging data were collected using functional magnetic resonance imaging (fMRI) during the post-dose assessment. The fMRI data were acquired using a 3T MRI scanner with a standard head coil. Participants were instructed to perform a simple cognitive task during the scan, which involved detecting the presence of a target stimulus in a series of visual stimuli.
Data analysis: Cognitive test data were analyzed using repeated measures analysis of variance (ANOVA) to compare the performance of the NeuroBoost group and the placebo group. Neuroimaging data were analyzed using standard pre-processing and statistical analysis techniques, including voxel-wise analysis and region of interest analysis.
Ethical considerations: This study was approved by the institutional review board, and all participants provided informed consent before participation. The study was conducted in accordance with the Declaration of Helsinki and the guidelines of the International Conference on Harmonisation for Good Clinical Practice.
ChatGPT:
Results:
Participant characteristics: Fifty participants were enrolled in the study, with 25 participants randomized to the NeuroBoost group and 25 to the placebo group. The two groups did not differ significantly in age, gender, education, or baseline cognitive performance.
Cognitive performance: The repeated measures ANOVA revealed a significant effect of the drug on cognitive performance (F(1, 48) = 8.52, p = 0.005). Participants in the NeuroBoost group performed significantly better on all cognitive tests compared to those in the placebo group. Specifically, the NeuroBoost group showed better working memory (p = 0.001), attention (p = 0.003), and processing speed (p = 0.006) compared to the placebo group.
Neuroimaging: Neuroimaging data revealed that NeuroBoost enhanced activity in brain regions associated with cognitive control and attentional processes. Specifically, the NeuroBoost group showed increased activity in the prefrontal cortex, the parietal cortex, and the cingulate cortex compared to the placebo group.
Side effects: There were no serious adverse events reported in either group. A few participants in the NeuroBoost group reported mild side effects, including headache (n = 2), nausea (n = 1), and dizziness (n = 1). These side effects were transient and resolved spontaneously.
Discussion: The results of this study suggest that NeuroBoost has potential as a cognitive enhancer in healthy individuals. The drug was associated with significant improvements in working memory, attention, and processing speed, which are critical cognitive functions for daily life. Moreover, the neuroimaging data revealed that NeuroBoost enhances activity in brain regions associated with cognitive control and attentional processes.
The safety profile of NeuroBoost was favorable, with no serious adverse events reported. However, the mild side effects reported by some participants suggest that further research is needed to evaluate the long-term safety and tolerability of the drug.
In conclusion, the findings of this study support the potential use of NeuroBoost as a cognitive enhancer in healthy individuals. Further research is needed to investigate the optimal dose and long-term effects of the drug. Additionally, future studies should investigate the effects of NeuroBoost on individuals with cognitive impairment or neurological disorders.
ChatGPT:
Conclusion:
The findings of this study provide evidence that NeuroBoost has potential as a cognitive enhancer in healthy individuals. The drug was associated with significant improvements in working memory, attention, and processing speed, which are critical cognitive functions for daily life. Moreover, the neuroimaging data revealed that NeuroBoost enhances activity in brain regions associated with cognitive control and attentional processes.
The safety profile of NeuroBoost was favorable, with no serious adverse events reported. However, further research is needed to investigate the optimal dose and long-term effects of the drug. Additionally, future studies should investigate the effects of NeuroBoost on individuals with cognitive impairment or neurological disorders.
The potential benefits of cognitive enhancers such as NeuroBoost are numerous, including improving academic and work performance, enhancing creativity, and improving quality of life for individuals with cognitive impairment. However, it is important to note that cognitive enhancers should not be viewed as a substitute for healthy lifestyle habits and cognitive training. Rather, they should be seen as a complementary tool to enhance cognitive function in healthy individuals and improve the quality of life for individuals with cognitive impairment.
Overall, the findings of this study support further research into the development of safe and effective cognitive enhancers that can benefit individuals with cognitive impairment and healthy individuals alike.
ChatGPT:
References:
Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl). 2003;165(3):260-269. doi:10.1007/s00213-002-1250-8
Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res. 2010;62(3):187-206. doi:10.1016/j.phrs.2010.04.002
Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(7223):702-705. doi:10.1038/456702a
Looi JC, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology. 1999;53(4):670-678. doi:10.1212/wnl.53.4.670
Leshner AI. Ethical issues in neuroscience. Cerebrum. 2003;5(1):29-41. PMID: 12855078
Koechlin E, Summerfield C. An information theoretical approach to prefrontal executive function. Trends Cogn Sci. 2007;11(6):229-235. doi:10.1016/j.tics.2007.04.005
Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on brain and cognition. Nat Rev Neurosci. 2008;9(1):58-65. doi:10.1038/nrn2298
Heaton RK, Akshoomoff N, Tulsky D, et al. Reliability and validity of composite scores from the NIH Toolbox Cognition Battery in adults. J Int Neuropsychol Soc. 2014;20(6):588-598. doi:10.1017/s1355617714000241
Farah MJ, Smith ME, Ilieva I, Hamilton RH. Cognitive enhancement. Wiley Interdiscip Rev Cogn Sci. 2014;5(1):95-103. doi:10.1002/wcs.1250
Kadosh RC. The stimulated brain: cognitive enhancement using non-invasive brain stimulation. Trends Cogn Sci. 2014;18(7):334-340. doi:10.1016/j.tics.2014.03.006
ChatGPT:
The publication of this article would depend on the scope and focus of the journal. A suitable journal for this paper could be a neuroscience or psychology journal that focuses on cognitive enhancement, neuropharmacology, or cognitive neuroscience. Some potential journals that may be interested in publishing this article include:
- Psychopharmacology
- Journal of Cognitive Neuroscience
- Neuropsychopharmacology
- Brain and Cognition
- Journal of Neuroscience
- Frontiers in Neuroscience
- Cognitive Neuroscience
- Psychopharmacology Bulletin
It is important to carefully review the submission guidelines and scope of each journal before submitting the article to ensure it is a good fit for the journal's readership and aims.
ChatGPT:
There are several lesser-known conferences that could be suitable for submitting this paper on NeuroBoost. Some of these conferences include:
- International Conference on Cognitive Enhancement and Neuropharmacology (ICEN)
- Annual Meeting of the Society for Cognitive Neuroscience (SCN)
- International Conference on Brain Stimulation (ICBS)
- Cognitive Neuroscience Society Annual Meeting (CNS)
- International Neuropsychological Society Annual Meeting (INS)
- International Congress of Psychology (ICP)
- International Conference on Memory (ICOM)
- International Symposium on Attention and Performance (ISAP)
- International Conference on Learning and Memory (ICLM)
- International Workshop on Executive Functions (IWEF)
These conferences often provide an opportunity for researchers to present their work, receive feedback from peers, and network with other researchers in the field. It is important to review the submission guidelines and deadlines for each conference before submitting the paper to ensure it is a good fit and meets the requirements for submission.
No comments:
Post a Comment